Purple Biotech Ltd
TASE:PPBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.7), the stock would be worth ₪2.87 (187% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.6 | ₪1 |
0%
|
| 3-Year Average | 1.7 | ₪2.87 |
+187%
|
| 5-Year Average | 5 | ₪8.22 |
+722%
|
| Industry Average | 5 | ₪8.23 |
+723%
|
| Country Average | 2.3 | ₪3.75 |
+275%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| IL |
P
|
Purple Biotech Ltd
TASE:PPBT
|
17.8m ILS | 0.6 | -0.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 31 | 39.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 6.8 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 5.9 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 5.9 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 5.2 | 15.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 6.1 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 1.8 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 6.4 | 16.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.3 |
| 70th Percentile | 4.2 |
| Max | 1 400.5 |
Other Multiples
Purple Biotech Ltd
Glance View
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
